Capricor Therapeutics, Inc.
CAPRNASDAQHealthcare● Active
$26.54
$-0.18(-0.66%)
Market Cap$1.2B
P/E Ratio—
52W High$40.37
52W Low$4.3
Capricor Therapeutics, Inc. (CAPR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CAPR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.59
Est. -$0.55 · -7.3%
Revenue
—
Est. $0.04B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
CAPR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.58 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.55 | -$0.59 | -7.3% | — | $0.04B | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.51 | -$0.62 | -21.6% | — | $0.00B | — |
| — Q4 FY2025 | Nov 10, 2025 | -$0.54 | -$0.54 | +0.0% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.48 | -$0.57 | -18.8% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.33 | -$0.53 | -60.6% | — | $0.00B | — |
| ▲ Q1 FY2025 | Mar 19, 2025 | -$0.31 | -$0.16 | +48.4% | $0.01B | $0.01B | +102.4% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.36 | -$0.38 | -5.6% | $0.00B | $0.01B | -77.1% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.58
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.59
EPS Est.
-$0.55
EPS Surpr.
-7.3%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.62
EPS Est.
-$0.51
EPS Surpr.
-21.6%
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.54
EPS Est.
-$0.54
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.57
EPS Est.
-$0.48
EPS Surpr.
-18.8%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.53
EPS Est.
-$0.33
EPS Surpr.
-60.6%
Revenue
—
Q1 FY2025
Mar 19, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.31
EPS Surpr.
+48.4%
Revenue
$0.01B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.38
EPS Est.
-$0.36
EPS Surpr.
-5.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.14 | $-0.11 | $-0.08 | 2 |
| Q3 FY2027 | $-0.25 | $-0.19 | $-0.14 | 2 |
| Q2 FY2027 | $-0.38 | $-0.29 | $-0.21 | 2 |
| Q1 FY2027 | $-0.47 | $-0.36 | $-0.26 | 2 |
| Q4 FY2026 | $0.10 | $0.14 | $0.18 | 4 |
| Q3 FY2026 | $0.26 | $0.36 | $0.42 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -7.3% | $31.90 | $31.52 | -1.19% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -21.6% | $33.57 | $33.42 | -0.45% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +0.0% | $5.93 | $5.56 | -6.24% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -18.8% | $9.07 | $7.82 | -13.78% |
| ▼ Q2 FY2025 | May 13, 2025 | -60.6% | $7.11 | $7.30 | +2.67% |
| ▲ Q1 FY2025 | Mar 19, 2025 | +48.4% | $11.61 | $12.22 | +5.25% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -5.6% | $18.10 | $16.91 | -6.57% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +2.8% | $3.91 | $3.56 | -8.95% |
Q2 FY2026-1.19%
Report Date
May 12, 2026
EPS Beat/Miss
-7.3%
Price Before
$31.90
Price After
$31.52
Q1 FY2026-0.45%
Report Date
Mar 12, 2026
EPS Beat/Miss
-21.6%
Price Before
$33.57
Price After
$33.42
Q4 FY2025-6.24%
Report Date
Nov 10, 2025
EPS Beat/Miss
+0.0%
Price Before
$5.93
Price After
$5.56
Q3 FY2025-13.78%
Report Date
Aug 11, 2025
EPS Beat/Miss
-18.8%
Price Before
$9.07
Price After
$7.82
Q2 FY2025+2.67%
Report Date
May 13, 2025
EPS Beat/Miss
-60.6%
Price Before
$7.11
Price After
$7.30
Q1 FY2025+5.25%
Report Date
Mar 19, 2025
EPS Beat/Miss
+48.4%
Price Before
$11.61
Price After
$12.22
Q4 FY2024-6.57%
Report Date
Nov 13, 2024
EPS Beat/Miss
-5.6%
Price Before
$18.10
Price After
$16.91
Q3 FY2024-8.95%
Report Date
Aug 7, 2024
EPS Beat/Miss
+2.8%
Price Before
$3.91
Price After
$3.56
Avg Beat Reaction-3.31%
Avg Miss Reaction-3.86%
Beat Rate3 / 8 quarters
Largest Move-13.78% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CAPR ends December
Capricor Therapeutics, Inc. (CAPR) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.59 — missing the analyst consensus of $-0.55 by -7.3%. The next CAPR earnings date is expected around September 1, 2026.
Each quarter, investors track CAPR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CAPR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CAPR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CAPR earnings · 5 questionsCapricor Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CAPR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CAPR historically reports after market close (AMC).
CAPR earnings datewhen is CAPR earningsCAPR next earnings datewhen does CAPR report earningsCAPR earnings calendar
▸ Source: FMP · Capricor Therapeutics, Inc. SEC filings · US GAAP · Capricor Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026